A drug stock with a safe dividend? That's just what you need in this tough environment.
Stocks went on another rollercoaster ride Friday, opening sharply lower before a series of ups, downs and curves, and an afternoon burst of bargain hunting that sent the Dow up more than 200 points.
The Dow Industrials has shown some significant moves each day over the past two weeks. In fact, yesterday the Dow was up 10% from its session low to session high.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.
In a market as treacherous as this one, that cash cushion could bring the protection you need.
Don't blindly chase this bounce. Be smart and know the playbook to battle the bear.
Of course not! But that's what Fox Business would have you believe. Allow us to set the record straight.
Will history repeat itself? Cramer offers strategies and stocks for surviving the coming week.
Stocks got an early boost from Buffett's vote of confidence in Wall Street but the meandering hearings on the bailout sucked the air out of the trading floor. By the closing bell, financials had fallen and only techs were left carrying the torch of hope.
As I watched Yankee legends and their families take the field last night before the final game at the 85 year old House that Ruth Built, I was amazed again by how many winning years they have had. 26 World Series Championships in 85 years - the most wins of any professional sports franchise in history. Did the positive energy from the wins flow down the East River to Wall St. and lift the markets those years?
The Lightning Round is extended in this CNBC.com exclusive feature.
Schering-Plough said Friday it will cut 1,000 sales jobs as part of broader cuts in a move to reduce costs and reposition itself in an ever-changing industry.
As the press release that came with the book says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."
With the markets starting down again today before rebounding, here are the top ten 2-day percent and point moves for the major indices. If the Dow closes down more than 23 points today, it would reach a top 10 point move. The S&P would need to close down less than 1 point to reach a top ten status. The Nasdaq is far from a top ten 2-day point or % move.
Plus, Cramer make the call on IBM, CSX, Celgene and more.
Jim Hardesty sees the glass more than half full. The strategist-economist of Hardesty Capital Management expects recovery -- and he has a few carefully-chosen stock picks.
The Democrats aren’t the only enemy of Big Pharma. The Fourth Estate has its own crusade against the group.
Stocks finished lower Tuesday as weakness in technology stocks sucked the air out the earlier rally inspired by oil's drop and the dollar's surge.
Stocks came charging out of the gate, inspired by oil's drop and the dollar's surge, but weakness in technology stocks sucked the air out of the rally.
While I was on the "New England Journal of Medicine" Web site yesterday preparing my reports for today about the embargoed articles, I noticed a banner ad at the top of the homepage from Eli Lilly saying something along the lines of, "Coming Soon: Effient (Prasugrel)."